This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Nateglinide: a Double Blind Add-on Study With Pioglitazone for Type 2 Diabetic Patients

This study has been completed.
Ajinomoto USA, INC.
Information provided by:
Astellas Pharma Inc Identifier:
First received: September 13, 2005
Last updated: March 11, 2008
Last verified: March 2008
The purpose of this study is to investigate the superiority of nateglinide over placebo for inadequately controlled type 2 diabetic patients with pioglitazone treatment.

Condition Intervention Phase
Type 2 Diabetes Mellitus Diabetes Mellitus, Type II Drug: nateglinide Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment

Resource links provided by NLM:

Further study details as provided by Astellas Pharma Inc:


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Type 2 diabetes mellitus under the treatment with pioglitazone

Exclusion Criteria:

  • Patients who cannot follow the diet therapy and/or exercise therapy
  • Type 1 diabetes mellitus
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00189774

Chubu region, Japan
Chugoku region, Japan
Hokkaido region, Japan
Kanto region, Japan
Kinki region, Japan
Kyushu region, Japan
Tohoku region, Japan
Sponsors and Collaborators
Astellas Pharma Inc
Ajinomoto USA, INC.
Study Director: Study Director Astellas Pharma Inc
  More Information Identifier: NCT00189774     History of Changes
Other Study ID Numbers: 026-CL-004
Study First Received: September 13, 2005
Last Updated: March 11, 2008

Keywords provided by Astellas Pharma Inc:
combination drug therapy

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Hypoglycemic Agents
Physiological Effects of Drugs processed this record on June 22, 2017